ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022Data reinforce ViiV Healthcare’s leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention London, 7 February 2022 – ViiV Healthca...

Related Keywords

London ,City Of ,United Kingdom ,United States ,Brentford ,Hounslow ,North Carolina ,Washington ,Philadelphia ,Pennsylvania ,Middlesex ,United Kingdom General ,Kimberly Smith ,Kathleen Quinn ,Dan Smith ,Josh Williams ,Jeff Mclaughlin ,Sonya Ghobrial ,Mick Readey ,Tim Foley ,James Dodwell ,Melinda Stubbee ,Nick Stone ,Glaxosmithkline ,Company Annual Report On Form ,Pfizer ,Pfizer Inc ,Shionogi Limited ,Viiv Healthcare ,Head Of Research Development At Viiv Healthcare ,Opportunistic Infections ,Parent Experiences ,Long Acting Injectables ,More Options ,Adolescents Study ,Early Detection ,Safety Information ,Fetal Toxicity ,Severe Hepatomegaly ,Virologic Response Due ,Drug Interactions ,Reconstitution Syndrome ,Prescribing Information ,Antiretroviral Pregnancy Registry ,Reproductive Potential ,European Summary ,Product Characteristics ,Drug Reaction ,Systemic Symptoms ,Injection Reactions ,Adverse Reactions ,Acting Properties ,Potential Associated Risks ,Annual Report ,